

Small-diameter melanomas (micromelanomas): clinical, dermoscopic and histopathological findings[☆]



Dear Editor,

Melanoma is one of the cancers with the highest rates of increase in the last decades. Traditionally, mass education strategies have emphasized the importance of melanomas of > 6 mm (ABCDE rule).^{1,2} However, the optimization of diagnostic methods, principally using dermoscopy, allows the early identification of melanomas smaller than this (micromelanomas). These may represent up to a third of all melanomas.³⁻⁵ For this reason, we decided to characterize the clinic, dermoscopy, and histopathology of micromelanomas in our institution.

A retrospective study in the Dermatology Department of the Hospital Clínico de la *Universidad de Chile*, with all patients that had a diagnosis of cutaneous melanoma with a clinical diameter up to 5 mm, between January 1st, 2003, and December 31, 2018, were included. The following characteristics were evaluated: sex, age, location, clinical

diameter, dermoscopy (evaluated by two dermatologists separately) and clinical diagnosis, as well as histopathological characteristics such as diagnosis (in situ or invasive), Breslow Index (BI), and ulceration. Descriptive statistics were applied using absolute numbers, percentages, averages, and standard deviation.

A total of 20 patients were evaluated (Table 1), 15 women (75%), and the mean age was 50.4 years (± 13.4 ; range 28–79 years). The most common location was the lower limbs (9/20), followed by the head/neck (5/20), trunk (4/20), and upper limbs (2/20). The mean clinical diameter was 3.7 mm (± 1.0 ; range 2–5 mm). The most frequent clinical diagnosis was atypical nevus (9/20), followed by melanocytic nevus (5/20), melanoma (5/20), and seborrheic keratosis (1/20). There was a photographic record of dermoscopy as much as twelve lesions, and an atypical network pattern was found in 6/12 (Fig. 1A and B), followed by irregular dots/globules (3/12), irregular hyperpigmented areas (3/12), and atypical blotches (2/12) (Fig. 2A and B). From the histopathological study: 12 cases (60%) showed in situ melanomas and the other 8 (40%) invasive melanomas, with a BI between 0.25 and 2.8 mm. None of the lesions showed ulceration. In two cases sentinel node biopsy was carried out, with negative results.

Table 1 Clinical, dermatoscopic and histopathological features of micromelanomas (n = 20).

Case	Sex/age	Clinical diagnosis	Location	Size (mm)	Histopathological diagnosis	Breslow index (mm)	Dermoscopy: main pattern	Dermoscopy: melanoma criteria
1	F/44	Atypical nevus	Trunk	4	In situ	N/A	Reticular	AN, IHA
2	F/45	Atypical nevus	Upper limbs	4	In situ	N/A	Reticular	AN, IG
3	M/72	Atypical nevus	Trunk	4	Invasive	0.75	Multicomponent	TSA, AB, SWS
4	F/45	Melanoma	Lower limbs	2	In situ	N/A	N/R	N/R
5	M/44	Melanoma	Lower limbs	3	Invasive	1.2	N/R	N/R
6	F/50	Nevus	Lower limbs	5	Invasive	0.25	Reticular	AN
7	F/60	Melanoma	Head/neck	3	In situ	N/A	Reticular	AN
8	M/52	Intradermal nevus	Head/neck	5	Invasive	2.8	N/R	N/R
9	F/61	Nevus	Head/neck	3	In situ	N/A	N/R	N/R
10	M/50	Melanoma	Head/neck	5	Invasive	0.9	Reticular	AN
11	F/79	Nevus	Head/neck	2	Invasive	0.8	N/R	N/R
12	F/30	Atypical nevus	Lower limbs	3	In situ	N/A	N/R	N/R
13	F/40	Atypical nevus	Upper limbs	3	In situ	N/A	Globular	IG
14	F/28	Atypical nevus	Lower limbs	5	In situ	N/A	Bicomponent ^a	IHA
15	F/36	Seborrheic keratosis	Trunk	5	Invasive	0.7	N/R	N/R
16	F/68	Atypical nevus	Lower limbs	3	Invasive	0.4	Structureless	AB
17	F/44	Atypical nevus	Lower limbs	3	In situ	N/A	Reticular	AN
18	F/46	Atypical nevus	Lower limbs	3	In situ	N/A	N/R	N/R
19	M/64	Nevus	Trunk	5	In situ	N/A	Bicomponent ^a	IG
20	F/50	Melanoma	Lower limbs	4	In situ	N/A	Bicomponent ^a	IHA

F, Female; M, Male; N/A, Not Applicable; N/R, Not Registered; AN, Atypical Network; TSA, Tan Structureless Areas; AB, Atypical Blotches; IG, Irregular dots/Globules; SWS, Shiny White Structures; IHA, Irregular Hyperpigmented Areas.

^a Bicomponent with the reticular pattern associated.

[☆] Study conducted at the Hospital Clínico Universidad de Chile, Santiago, Chile.




Figure 1 (A), In situ melanoma. Clinical diameter of 4 mm. (B), Dermoscopy shows an atypical network with irregular hyperpigmented areas.




Figure 2 (A), Invasive melanoma of 0.75 mm in Breslow thickness with a diameter of 3 mm. (B), Dermoscopy shows a multi-component pattern with tan structureless areas, atypical blotch, shiny white structures, and serpentine vessels.

The present study is the first series of micromelanomas in Latin American patients. We point out the high percentage of invasive melanomas, including one case with a BI over 2 mm. This is similar to that shown in other studies which have reported between 27% and 45% invasive melanomas.^{1,3,6} However, Bono et al., reported an invasive component in 19 of their 23 lesions of 3 mm or less (83%). This is highly noteworthy and worrying, given that it contrasts with classical thinking which suggests that small lesions are early-stage lesions.²

Strategies for the early detection of melanomas, like the ABCDE rule, are not very efficient for recognizing micromelanomas. A clinical characteristic suggested by several authors is the greater frequency and intensity of black coloration. This suggests the possibility of changing the ABCDE rule, with 'Dark' replacing 'Diameter' as the letter 'D' for these lesions.⁶ However, it should be noted the poor utility of this rule in nodular melanomas, which may represent an important part of thicker micromelanomas.

As for the dermoscopy, we observed a more frequent atypical network, irregular dots/globules, and irregular hyperpigmented areas, as described in the literature.^{3,7} According to Seidenari et al., micromelanomas lack many of the characteristics that larger lesions have, as they are less asymmetrical, have fewer colors, and have a lower

frequency of a regression. They also have practically no atypical vessels or blue-white veil, and this undoubtedly makes diagnosis more difficult.³

Small diameter melanocytic lesions should be evaluated in the same way as larger lesions, because if they turn out to be melanomas the possibility, they will be invasive is not low, as our study shows.

Financial support

None declared.

Authors' contributions

Pablo Vargas-Mora: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the literature; critical review of the manuscript.

Rubén González-Cuevas: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in

research orientation; critical review of the literature; critical review of the manuscript.

Leonardo Peruilh-Bagolini: Approval of the final version of the manuscript; conception and planning of the study; elaboration and writing of the manuscript; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the manuscript.

Fernando Valenzuela: Approval of the final version of the manuscript; conception and planning of the study; obtaining, analyzing, and interpreting the data; effective participation in research orientation; critical review of the manuscript.

Conflicts of interest

None declared.

References

1. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy W, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. *JAMA*. 2004;292:2771–6.
2. Bono A, Tolomio E, Trincon S, Bartoli C, Tomatis S, Carbone A, et al. Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. *Br J Dermatol*. 2006;155:570–3.
3. Seidenari S, Ferrari C, Borsari S, Fabiano A, Bassoli S, Giusti F, et al. Dermoscopy of small melanomas: just miniaturized dermoscopy? *Br J Dermatol*. 2014;171:100613.

4. Pellizzari G, Magee J, Weedon D, Rosendahl C. A tiny invasive melanoma: a case report with dermatoscopy and dermatopathology. *Dermatol Pract Concept*. 2013;3:4951.
5. Drugge ED, Volpicelli ER, Sarac RM, Strang SR, Elston DM, Drugge RJ. Micromelanomas identified with time-lapse total body photography and dermoscopy. *J Am Acad Dermatol*. 2018;78:182–3.
6. Goldsmith SM, Solomon AR. A series of melanomas smaller than 4 mm and implications for the ABCDE rule. *J Eur Acad Dermatol Venereol*. 2007;21:929–34.
7. Megaris A, Lallas A, Bagolini LP, Papageorgiu C, Spyridis I, Apalla Z. Dermoscopic features of melanomas with a diameter up to 5 mm (micromelanomas): a retrospective study. *J Am Acad Dermatol*. 2020;83:1160–1.

Pablo Vargas-Mora *, Rubén González-Cuevas , Leonardo Peruilh-Bagolini , Fernando Valenzuela 

Department of Dermatology, Faculty of Medicine, Universidad de Chile, Santiago, Chile

* Corresponding author.

E-mail: pablovargas.med@gmail.com (P. Vargas-Mora).

Received 22 August 2020; accepted 5 October 2020
available online 20 November 2021

<https://doi.org/10.1016/j.abd.2020.10.014>

0365-0596/ © 2021 Sociedade Brasileira de Dermatologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis[☆]



Dear Editor,

Psoriasis is an inflammatory, chronic and recurrent disease with evident genetic influence. The intensity, extension and different manifestations associated with the disease guide therapeutic decisions. Advances in the knowledge of the disease immunopathology over the last decades have culminated in the development of new medications, called immunobiologicals, which act in a specific and precise way at different levels of the inflammatory cascade of psoriasis.¹ With the introduction of anti-tumor necrosis factor-alpha (anti-TNF- α) drugs: etanercept (ETA), infliximab (INF), adalimumab (ADA), and certolizumab pegol (CP), followed by inhibitors of interleukin-12/23, ustekinumab (UST); inhibitors of interleukin 17: secukinumab (SEC) and ixekizumab (IXE), and more recently inhibitors of interleukin 23 alone: Guselkumab (GUS) and Risankizumab (RISA), it has become possible to effectively treat severe and refractory forms of the disease, associated with a satisfactory safety profile. On the other hand, uncertainty regarding the

choice of the most appropriate drug, the long-term sustained response, and the possibility of interrupting therapy has an impact on the therapeutic decision.

Drug survival is defined as the time from the beginning to the discontinuation of a certain treatment. The time interval from the start of the treatment to its discontinuation, as well as the reasons for this outcome, whether due to loss of efficacy, complications, or treatment abandonment, may vary in different populations with psoriasis.^{2,3} To date, there are no data associating the therapeutic response to the survival time of immunobiologicals in patients with psoriasis in Brazil.

Aiming to determine the time of drug survival, a total of 229 treatments with immunobiological drugs were evaluated in 110 patients with moderate to severe psoriasis at Hospital das Clínicas, Universidade de São Paulo, in the state of São Paulo, Brazil, for a period of two years and analysed regarding the response to immunobiologicals, number of previous treatments and reason for discontinuation. The analysis of medical records also allowed the collection of data in relation to previous treatments since the introduction of immunobiologicals as a therapeutic option. Drug survival was defined as the time from the start of the treatment with the immunobiological, that is, the first dose until the occurrence of the event of interest (temporary/definitive discontinuation of treatment). Kaplan-Meier curves were used to estimate each of the drug survival prob-

[☆] Study conducted at the Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil.